29-Nov-2021

GBM AGILE Opens to Paxalisib in Canada

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health Sciences Centre in Toronto, Ontario. This marks the first Canadian site to open to paxalisib, and the first opportunity for Canadian patients to access the drug.

15-Nov-2021

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Office

In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States.

11-Nov-2021

PNOC Study in Childhood Brain Cancer Enrols First Patient

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient successfully enrolled to the study.

08-Nov-2021

Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial

Kazia Therapeutics Ltd's CEO Dr James Garner tells Proactive they've officially enrolled the first patient in its investigational cancer therapy trial. The oncology-focused drug development company licensed the cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021. The phase one study will focus primarily on understanding the safety, tolerability and pharmacokinetics of EVT801 across a range of doses.

04-Nov-2021

Kazia Enrols First Patient to EVT801 Phase I Clinical Trial

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec SE in April 2021.

26-Oct-2021

Edison TV: Kazia Therapeutics – introducing novel asset EVT-801

Kazia Therapeutics is an oncology focused drug development company based in Sydney, Australia. In addition to Kazia’s lead programme, paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway developed to treat the most common form of brain cancer, the company is developing EVT-801, a small molecule inhibitor of VEGFR3. Preclinical data have shown EVT-801 to be active against a broad range of tumor types.

14-Sep-2021

Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Kazia Therapeutics Ltd's Dr James Garner speaks with Proactive at the ASX Small and Mid Cap Conference. Its lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

21-Jul-2021

Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease.

22-Apr-2021

Biotech Dispatch: Kazia licenses global rights to potential first-in-class oncology drug

Kazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and a master services agreement with European company Evotec SE for EVT801, a small molecule, first-in-class oncology drug candidate.

21-Apr-2021

Ausbiz: Three big moves in seven weeks; how Kazia is turbocharging biotech innovation

Three big moves in seven weeks; how Kazia is turbocharging biotech innovation

Kazia Therapeutics CEO James Garner is a very happy man. After securing the company's third key licence in seven weeks, he tells us about the why's and how's.

21-Apr-2021

Stockhead: Kazia Therapeutics completes third licensing deal in seven weeks

Kazia Therapeutic‘s chief executive says he could do with catching up on sleep after a “whirlwind” seven weeks in which the $185 million cancer-focused Sydney biotech completed three different cross-border licensing deals.

Kazia on Monday announced it had licensed global rights to a promising small molecule oncology drug candidate from Germany-based Evotec SE (FRA:EVT) for an upfront payment of €1 million ($1.6 million), plus contingent milestone payments of up to €308 million ($480 million).

20-Feb-2021

Edison TV: Kazia Therapeutics - overview and update with CEO James Garner

Kazia Therapeutics (KZA) is an oncology-focused drug development company. Its drug candidates are designed to treat diseases which are poorly served by existing therapies. In this video, James Garner, CEO, highlights the company’s business model, newest drug asset and progress over the next year.

09-Feb-2021

Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Kazia Therapeutics Ltd's Dr James Garner speaks with Proactive at the ASX Small and Mid Cap Conference. Its lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

11-Dec-2020

Associate Professor Matt Dun talks about the PNOC study in DIPG

Our collaborator, Associate Professor Matt Dun talks about the new PNOC study in an article for the Hunter Medical Research Institute (HMRI).

20-Oct-2020

CEO Dr James Garner interview with Proactive Investors on GBM AGILE

We’re pleased to share a video interview with our CEO, Dr James Garner on Proactive Investors following the recent commencement of the GBM AGILE study, which will serve as the pivotal study for registration of our lead candidate, paxalisib.

06-Oct-2020

Ausbiz, The Wall Street Transcript and Stockhead media articles

Our CEO, Dr James Garner was recently interviewed on Ausbiz to discuss Kazia’s entitlement offer, with the company successfully completing the institutional component of the offer last week, which raised $16.4 million.

28-Sep-2020

CEO, Dr James Garner interviewed by Share Café on Dana Farber collaboration

Our CEO, Dr James Garner recently conducted a video interview with Share Café following Kazia’s announcement of a collaboration with Dana-Farber Cancer Institute to investigate the use of paxalisib in primary central nervous system (CNS) lymphoma, a potential new indication for the drug.